GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (WBO:LLYC) » Definitions » Cyclically Adjusted Price-to-FCF

Eli Lilly and Co (WBO:LLYC) Cyclically Adjusted Price-to-FCF : 214.52 (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Price-to-FCF?

As of today (2024-04-29), Eli Lilly and Co's current share price is €688.60. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was €3.21. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is 214.52.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

WBO:LLYC' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.08   Med: 28.05   Max: 221.53
Current: 206.95

During the past years, Eli Lilly and Co's highest Cyclically Adjusted Price-to-FCF was 221.53. The lowest was 13.08. And the median was 28.05.

WBO:LLYC's Cyclically Adjusted Price-to-FCF is ranked worse than
92.35% of 327 companies
in the Drug Manufacturers industry
Industry Median: 32.38 vs WBO:LLYC: 206.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share data for the three months ended in Dec. 2023 was €-1.992. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €3.21 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Price-to-FCF Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 44.71 68.58 84.88 164.46

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.88 77.20 109.24 137.06 164.46

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.



Eli Lilly and Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=688.60/3.21
=214.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.992/129.4194*129.4194
=-1.992

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.047 99.695 0.061
201406 0.546 100.560 0.703
201409 0.975 100.428 1.256
201412 0.511 99.070 0.668
201503 -0.410 99.621 -0.533
201506 0.492 100.684 0.632
201509 0.653 100.392 0.842
201512 0.381 99.792 0.494
201603 -0.315 100.470 -0.406
201606 0.971 101.688 1.236
201609 1.205 101.861 1.531
201612 1.374 101.863 1.746
201703 -0.585 102.862 -0.736
201706 1.204 103.349 1.508
201709 1.139 104.136 1.416
201712 1.012 104.011 1.259
201803 0.155 105.290 0.191
201806 -0.283 106.317 -0.344
201809 1.521 106.507 1.848
201812 0.710 105.998 0.867
201903 -0.080 107.251 -0.097
201906 0.733 108.070 0.878
201909 1.156 108.329 1.381
201912 1.609 108.420 1.921
202003 0.110 108.902 0.131
202006 1.923 108.767 2.288
202009 1.296 109.815 1.527
202012 0.895 109.897 1.054
202103 1.110 111.754 1.285
202106 1.134 114.631 1.280
202109 1.097 115.734 1.227
202112 1.685 117.630 1.854
202203 1.645 121.301 1.755
202206 0.387 125.017 0.401
202209 1.748 125.227 1.807
202212 1.068 125.222 1.104
202303 0.855 127.348 0.869
202306 -0.209 128.729 -0.210
202309 -1.887 129.860 -1.881
202312 -1.992 129.419 -1.992

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (WBO:LLYC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (WBO:LLYC) Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (WBO:LLYC) Headlines

No Headlines